Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955188208> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2955188208 endingPage "S199" @default.
- W2955188208 startingPage "S199" @default.
- W2955188208 abstract "Today, near normal life expectancy among people living with HIV infection, translates into life-long exposure to antiretroviral treatment (ART). Reducing drug burden without compromising efficacy via a 2-drug regimen could reduce ART-associated long-term toxicity, and potentially generate significant savings to the health care system compared to traditional 3-drug regimens (3DR). Two recent phase III trials (GEMINI 1&2) have demonstrated the non-inferiority of dolutegravir plus lamivudine (DTG+3TC) versus DTG plus tenofovir disoproxil and emtricitabine (TDF/FTC), in achieving virologic suppression at week 48. A network meta-analysis (NMA) comparing DTG/3TC with other ART regimens recommended by the US Department of Health and Human Services showed numerical differences in efficacy and safety versus 3DRs. This study aimed to evaluate the cost-effectiveness of DTG/3TC in the US, in treatment naïve HIV-infected patients. A cost-utility analysis using a hybrid decision-tree and Markov model was run probabilistically to estimate total lifetime costs and quality-adjusted life years (QALYs) of DTG/3TC versus recommended regimens. Health states were defined by viral load and CD4-cell count. Efficacy and safety data were derived from GEMINI trials and the NMA. Costs (inflated to 2017 USD) were obtained from published literature and discounted at 3% annually. Current branded drug acquisition prices were included for all ART regimens. Versus most comparators (including Bictegravir/TAF/FTC), DTG/3TC was dominant, with incremental QALYs ranging from 0.016 to 0.203 across these comparisons. Further, driven by the lower cost of DTG/3TC, significant cost-savings were observed across all comparisons (cost savings of $48,047 to $157,080). Assuming a willingness-to-pay threshold of $100,000/QALY, the likelihood of cost-effectiveness was estimated to be >99% across all comparisons. Results suggest that DTG/3TC is a highly cost-effective regimen for US payers, providing similar efficacy to recommended regimens, while offering the potential for marginal QALY gains and significant cost savings in the treatment of naïve HIV-patients." @default.
- W2955188208 created "2019-07-12" @default.
- W2955188208 creator A5013323581 @default.
- W2955188208 creator A5016873957 @default.
- W2955188208 creator A5018278249 @default.
- W2955188208 creator A5022177259 @default.
- W2955188208 creator A5023247190 @default.
- W2955188208 creator A5074572540 @default.
- W2955188208 date "2019-05-01" @default.
- W2955188208 modified "2023-09-30" @default.
- W2955188208 title "PIN31 DOLUTEGRAVIR PLUS LAMIVUDINE FOR THE TREATMENT OF ART NAIVE ADULTS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): A US COST-UTILITY ANALYSIS" @default.
- W2955188208 doi "https://doi.org/10.1016/j.jval.2019.04.902" @default.
- W2955188208 hasPublicationYear "2019" @default.
- W2955188208 type Work @default.
- W2955188208 sameAs 2955188208 @default.
- W2955188208 citedByCount "0" @default.
- W2955188208 crossrefType "journal-article" @default.
- W2955188208 hasAuthorship W2955188208A5013323581 @default.
- W2955188208 hasAuthorship W2955188208A5016873957 @default.
- W2955188208 hasAuthorship W2955188208A5018278249 @default.
- W2955188208 hasAuthorship W2955188208A5022177259 @default.
- W2955188208 hasAuthorship W2955188208A5023247190 @default.
- W2955188208 hasAuthorship W2955188208A5074572540 @default.
- W2955188208 hasBestOaLocation W29551882081 @default.
- W2955188208 hasConcept C112930515 @default.
- W2955188208 hasConcept C126322002 @default.
- W2955188208 hasConcept C133925201 @default.
- W2955188208 hasConcept C142462285 @default.
- W2955188208 hasConcept C159047783 @default.
- W2955188208 hasConcept C2522874641 @default.
- W2955188208 hasConcept C2777869810 @default.
- W2955188208 hasConcept C2779502633 @default.
- W2955188208 hasConcept C2779778239 @default.
- W2955188208 hasConcept C2780593183 @default.
- W2955188208 hasConcept C2781413609 @default.
- W2955188208 hasConcept C2908647359 @default.
- W2955188208 hasConcept C2993143319 @default.
- W2955188208 hasConcept C3013748606 @default.
- W2955188208 hasConcept C3019080777 @default.
- W2955188208 hasConcept C64332521 @default.
- W2955188208 hasConcept C71924100 @default.
- W2955188208 hasConcept C99454951 @default.
- W2955188208 hasConceptScore W2955188208C112930515 @default.
- W2955188208 hasConceptScore W2955188208C126322002 @default.
- W2955188208 hasConceptScore W2955188208C133925201 @default.
- W2955188208 hasConceptScore W2955188208C142462285 @default.
- W2955188208 hasConceptScore W2955188208C159047783 @default.
- W2955188208 hasConceptScore W2955188208C2522874641 @default.
- W2955188208 hasConceptScore W2955188208C2777869810 @default.
- W2955188208 hasConceptScore W2955188208C2779502633 @default.
- W2955188208 hasConceptScore W2955188208C2779778239 @default.
- W2955188208 hasConceptScore W2955188208C2780593183 @default.
- W2955188208 hasConceptScore W2955188208C2781413609 @default.
- W2955188208 hasConceptScore W2955188208C2908647359 @default.
- W2955188208 hasConceptScore W2955188208C2993143319 @default.
- W2955188208 hasConceptScore W2955188208C3013748606 @default.
- W2955188208 hasConceptScore W2955188208C3019080777 @default.
- W2955188208 hasConceptScore W2955188208C64332521 @default.
- W2955188208 hasConceptScore W2955188208C71924100 @default.
- W2955188208 hasConceptScore W2955188208C99454951 @default.
- W2955188208 hasLocation W29551882081 @default.
- W2955188208 hasOpenAccess W2955188208 @default.
- W2955188208 hasPrimaryLocation W29551882081 @default.
- W2955188208 hasRelatedWork W2899935160 @default.
- W2955188208 hasRelatedWork W2921712889 @default.
- W2955188208 hasRelatedWork W2995070168 @default.
- W2955188208 hasRelatedWork W3033559713 @default.
- W2955188208 hasRelatedWork W3089405003 @default.
- W2955188208 hasRelatedWork W3132316057 @default.
- W2955188208 hasRelatedWork W3161017411 @default.
- W2955188208 hasRelatedWork W3177431642 @default.
- W2955188208 hasRelatedWork W4295486710 @default.
- W2955188208 hasRelatedWork W4318927236 @default.
- W2955188208 hasVolume "22" @default.
- W2955188208 isParatext "false" @default.
- W2955188208 isRetracted "false" @default.
- W2955188208 magId "2955188208" @default.
- W2955188208 workType "article" @default.